J Clin Outcomes Manage
Use of RSV-IGIV: one hospital's experience
Lee KR, Teter BW, Margolis KA, DeVincenzo JP, Barrett FF
Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) is approved for prevention of RSV disease in children younger than 24 months with bronchopulmonary dysplasia or premature birth. The authors report on compliance and other outcomes in patients receiving this drug during 2 RSV seasons.
Search the Turner White index to find abstracts of articles published in JCOM.